MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

BofA raised the firm’s price target on Amgen (AMGN) to $294 from $275 and keeps an Underperform rating on the shares. For the last several ...

With proper data governance, the pharma industry can improve patient-centricity in trials and bring lifesaving therapies to ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Amgen (AMGN – Research Report), with a ...

Nichols & Pratt Advisers LLP MA reduced its Amgen holdings by 20.1%, selling 835 shares in Q4. Despite this, institutional ...

In this article, we will look at the 11 Best Undervalued Stocks to Invest in Now.

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Proficio Capital Partners LLC massively increased its stake in Amgen, acquiring 470,808 shares in Q4. This move significantly ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.